FluroTech Ltd. (TEST.V)
| Previous Close | 0.0150 |
| Open | 0.0100 |
| Bid | 0.0100 x 0 |
| Ask | 0.0150 x 0 |
| Day's Range | 0.0100 - 0.0150 |
| 52 Week Range | 0.0100 - 0.1950 |
| Volume | |
| Avg. Volume | 48,395 |
| Market Cap | 1.81M |
| Beta (5Y Monthly) | -1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0880 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
FluroTech Provides Operational Update: Announces Pause on Further Development of its Pandemic and Emerging Disease Defense Platform
CALGARY, Alberta, April 08, 2022 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (the “Company” or “FluroTech”), announces that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require additional financing to c
- GlobeNewswire
FluroTest Provides System Development Update; Announces Further Progress Optimizing the Immunoassay for SARS-CoV-2 Detection
CALGARY, Alberta, Dec. 07, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a developer of diagnostics technology in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on its efforts to bring its Pandemic Response Platform to market. About FluroTest Diagnostic Systems Ltd. FluroTest, a diagnostics technology leader in surge
- GlobeNewswire
FluroTest Provides System Development Update; Reports Point of Access Test System and Immunoassay for SARS-CoV-2 Detection is Fully Functional
CALGARY, Alberta, Nov. 19, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a developer of diagnostics technology in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on its efforts to bring its Pandemic Response Platform to market. FluroTest has been developing its “Pandemic and Emerging Disease Defense Platform” since la
